vs 10,564 other HR bills in the 118th — cohort avg 68d
Summary
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
Lobbying filings that explicitly cite this bill (7)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Actions (3)
May 10, 2024
Referred to the Subcommittee on Health.
May 6, 2024
Referred to the House Committee on Energy and Commerce.
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $150,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $150,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $130,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; and H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
Client expense: $130,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; and H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
Client expense: $130,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 1117, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of ob-gyn units in rural hospitals on patient access to care and maternal morbidity and mortality; Impact of abortion restrictions on patient outcomes and the ob-gyn workforce (general); H.R. 3305/S. 1606, Black Maternal Health Momnibus Act; H.R. 1202/S. 704, Resident Education Deferred Interest (REDI) Act; H.R. 2389/S. 1302, Resident Physician Shortage Reduction Act of 2023; H.R. 2569, Doctors of Community (DOC) Act; Teaching Health Center Graduate Medication Education (general); H.R. 3838/S. 2415, Preventing Maternal Deaths Reauthorization Act of 2023; H.R. 3226/S. 1573, PREEMIE Reauthorization Act of 2023; Inclusion of pregnant and lactating individuals in research (general); Telemedicine (general); H.R. 5012/S. 2647, SHINE for Autumn Act; H.R. 4581/S. 2231, Maternal and Child Health Stillbirth Prevention Act; H.R. 7056/S. 3612, Access to Family Building Act; H.R. 7153/S. 3679, Dr. Lorna Breen Health Care Provider Protection Act; S.___, Supporting Healthy Moms and Babies Act; S. 712/H.R. 8532, Connected MOM Act; S. 4079/H.R. 8383, Rural Obstetrics Readiness Act; H.R.___, PRAMS for Dads Act; S. 4223, Access to Birth Control Act; H.Res.1248, National Menstrual Health Awareness Month Resolution; Diversity, Equity, and Inclusion in medicine (general); H.R 8715, NEST Act; S.___, Keep Obstetrics Local Act; H.R. 7855, Rural Residency Planning and Development Act; H.R.___, Diane Powis Ovarian Cancer Testing Access Act; H.R. 8247, Uterine Fibroids Intervention and Gynecological Health Treatment Act (UFIGHT); H.R. 4933/S. 462, Mental Health Professionals Workforce Shortage Loan Repayment Act; H.R. 7432, Sickle Cell Disease Comprehensive Care Act of 2024; S. 4445, Right to IVF Act; Implementation of P.L. 117-328, Pregnant Workers Fairness Act; H.R. 834/S. 230, Rural Physician Workforce Production Act; Rural Residency Planning and Development Program (general); National Health Service Corps (general); H.R. 3523/S. 1710, Perinatal Workforce Act; H.R. 3086, Find it Early Act; H.R. 8796/S. 4619, Stop Comstock Act; Health Insurance Portability and Accountability Act (general); Patient-physician relationship (general); Menopause research, training, and education (general); Alliance for Innovation on Maternal Health; Residency programs in obstetrics and gynecology (general); Abortion training in obstetrics and gynecology residency programs (general); Obstetrician-gynecologist workforce (general); Reproductive health data privacy (general); Substance use disorder during pregnancy (general); Physician burnout (general); Maternal mental health (general); Artificial intelligence in health care (general); Coverage for infertility (general); Protections for in vitro fertilization (general); Restrictions on menthol cigarettes and flavored cigars (general); Nicotine limits in cigarettes (general); White House Initiative on Womens Health Research (general); Pediatric Subspecialty Loan Repayment Program; Over-the-counter contraception (general); HPV vaccination (general); Cancer Moonshot Initiative; Remote patient monitoring (general); Fertility preservation services for sickle cell patients treated with cell and gene therapies; Prenatal screening (general);Prenatal supplements (general); Crisis pregnancy centers (general); Care for pregnant and postpartum incarcerated individuals (general); Congenital syphilis (general); Gun violence as a public health issue (general); Obstetric hemorrhage managements at the Indian Health Service (general); H.Res. 1180, Recognizing the importance of diversity, equity, and inclusion efforts in medical education.
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office